Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial

Abstract Background Patients with non‐small‐cell lung cancer (NSCLC) and uncommon EGFR alterations typically have worse treatment outcomes than patients with classically EGFR‐mutated NSCLC. This study aimed to investigate the efficacy and safety of PD‐1 blockade with sintilimab plus anti‐angiogenic...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Kaiyan Chen, Yanjun Xu, Zhiyu Huang, Xiaoqing Yu, Wei Hong, Hui Li, Xiaoling Xu, Hongyang Lu, Fajun Xie, Jun Chen, Youzu Xu, Yun Fan
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2023-10-01
Edice:	Cancer Medicine
Témata:	anlotinib anti‐angiogenic non‐small cell lung cancer (NSCLC) PD‐1 sintilimab uncommon EGFR mutations
On-line přístup:	https://doi.org/10.1002/cam4.6548
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!